S&P 500   3,844.67
DOW   31,142.65
QQQ   322.94
S&P 500   3,844.67
DOW   31,142.65
QQQ   322.94
S&P 500   3,844.67
DOW   31,142.65
QQQ   322.94
S&P 500   3,844.67
DOW   31,142.65
QQQ   322.94
Log in

Abiomed Stock Forecast, Price & News

+8.55 (+2.54 %)
(As of 01/20/2021 12:06 PM ET)
Today's Range
Now: $344.85
50-Day Range
MA: $300.28
52-Week Range
Now: $344.85
Volume7,387 shs
Average Volume323,137 shs
Market Capitalization$15.58 billion
P/E Ratio75.79
Dividend YieldN/A
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Abiomed logo


Overall MarketRank

1.46 out of 5 stars

Analyst Opinion: 1.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
Current SymbolNASDAQ:ABMD



Sales & Book Value

Annual Sales$840.88 million
Cash Flow$5.52 per share
Book Value$23.64 per share


Net Income$203.01 million


Market Cap$15.58 billion
Next Earnings Date1/28/2021 (Confirmed)
+8.55 (+2.54 %)
(As of 01/20/2021 12:06 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Abiomed (NASDAQ:ABMD) Frequently Asked Questions

How has Abiomed's stock price been impacted by Coronavirus (COVID-19)?

Abiomed's stock was trading at $151.13 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABMD shares have increased by 127.6% and is now trading at $344.00.
View which stocks have been most impacted by COVID-19

Is Abiomed a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abiomed in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Abiomed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares.
View analyst ratings for Abiomed
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Abiomed?

Wall Street analysts have given Abiomed a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Abiomed wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Abiomed's next earnings date?

Abiomed is scheduled to release its next quarterly earnings announcement on Thursday, January 28th 2021.
View our earnings forecast for Abiomed

How can I listen to Abiomed's earnings call?

Abiomed will be holding an earnings conference call on Thursday, January 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Abiomed's earnings last quarter?

Abiomed, Inc. (NASDAQ:ABMD) issued its quarterly earnings data on Tuesday, November, 3rd. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.87 by $0.49. The medical equipment provider earned $209.80 million during the quarter, compared to analyst estimates of $202.89 million. Abiomed had a net margin of 25.89% and a return on equity of 15.34%. The business's revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period last year, the firm earned $0.28 earnings per share.
View Abiomed's earnings history

What guidance has Abiomed issued on next quarter's earnings?

Abiomed issued an update on its third quarter 2021 Pre-Market earnings guidance on Thursday, October, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $221-230 million, compared to the consensus revenue estimate of $234.29 million.

What price target have analysts set for ABMD?

6 analysts have issued twelve-month target prices for Abiomed's shares. Their forecasts range from $155.00 to $320.00. On average, they anticipate Abiomed's stock price to reach $238.25 in the next twelve months. This suggests that the stock has a possible downside of 30.7%.
View analysts' price targets for Abiomed
or view Wall Street analyst' top-rated stocks.

Who are some of Abiomed's key competitors?

What other stocks do shareholders of Abiomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG), Square (SQ), Netflix (NFLX), Adobe (ADBE) and salesforce.com (CRM).

Who are Abiomed's key executives?

Abiomed's management team includes the following people:
  • Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 53, Pay $1.68M)
  • Mr. Todd A. Trapp, CFO & VP (Age 49, Pay $800.98k)
  • Dr. David M. Weber, Sr. VP & COO (Age 59, Pay $752.48k)
  • Mr. Michael G. Howley, VP & GM of Global Sales (Age 56, Pay $522.56k)
  • Mr. Andrew J. Greenfield, VP & Chief Commercial Officer (Age 47, Pay $547.39k)
  • Dr. Thorsten Siess Ph.D., VP & CTO
  • Ms. Ingrid Goldberg Ward, Director of Investor Relations
  • Mr. Marc A. Began, VP, Gen. Counsel & Sec. (Age 53)
  • Ms. Karen Mahoney, Head of Global HR
  • Dr. Charles A. Simonton M.D., VP & Chief Medical Officer

What is Abiomed's stock symbol?

Abiomed trades on the NASDAQ under the ticker symbol "ABMD."

Who are Abiomed's major shareholders?

Abiomed's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.17%), Rhenman & Partners Asset Management AB (0.14%), Autus Asset Management LLC (0.04%), Frontier Capital Management Co. LLC (0.03%), State of Alaska Department of Revenue (0.03%) and Crossmark Global Holdings Inc. (0.02%). Company insiders that own Abiomed stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Martin P Sutter, Michael R Minogue and Paul Thomas.
View institutional ownership trends for Abiomed

Which institutional investors are selling Abiomed stock?

ABMD stock was sold by a variety of institutional investors in the last quarter, including Brookstone Capital Management, Rhenman & Partners Asset Management AB, Scout Investments Inc., Frontier Capital Management Co. LLC, Autus Asset Management LLC, and First Hawaiian Bank. Company insiders that have sold Abiomed company stock in the last year include Andrew J Greenfield, Dorothy E Puhy, Martin P Sutter, Michael R Minogue, and Paul Thomas.
View insider buying and selling activity for Abiomed
or view top insider-selling stocks.

Which institutional investors are buying Abiomed stock?

ABMD stock was bought by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Exchange Traded Concepts LLC, State of Alaska Department of Revenue, 6 Meridian, IFM Investors Pty Ltd, and Louisiana State Employees Retirement System.
View insider buying and selling activity for Abiomed
or or view top insider-buying stocks.

How do I buy shares of Abiomed?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Abiomed's stock price today?

One share of ABMD stock can currently be purchased for approximately $344.00.

How big of a company is Abiomed?

Abiomed has a market capitalization of $15.55 billion and generates $840.88 million in revenue each year. The medical equipment provider earns $203.01 million in net income (profit) each year or $4.74 on an earnings per share basis. Abiomed employs 1,536 workers across the globe.

What is Abiomed's official website?

The official website for Abiomed is www.abiomed.com.

How can I contact Abiomed?

Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.